Neuromodulation for Brain Tumors: Myth or Reality? A Narrative Review by Quintino Giorgio D’Alessandris, Grazia Menna, Alessandro Izzo, Manuela D’Ercole, Giuseppe Maria Della Pepa, Liverana Lauretti, Roberto Pallini, Alessandro Olivi, Nicola Montano

“…We focus both on more traditional oncologic approaches, aimed at modulating the major pathways involved in cancer neuroscience through drugs or genetic engineering techniques, and on electric stimulation proposals; the latter is at the cutting-edge of neuro-oncology.…”
Get full text

Adding Value to Liquid Biopsy for Brain Tumors: The Role of Imaging by Nastaran Khalili, Hossein Shooli, Nastaran Hosseini, Anahita Fathi Kazerooni, Ariana Familiar, Sina Bagheri, Hannah Anderson, Stephen J. Bagley, Ali Nabavizadeh

“…Clinical management in neuro-oncology has changed to an integrative approach that incorporates molecular profiles alongside histopathology and imaging findings. …”
Get full text

Assessment of the hypervascularized fraction of glioblastomas using a volume analysis of dynamic susceptibility contrast-enhanced MRI may help to identify pseudoprogression by Margaux Roques, Isabelle Catalaa, Magali Raveneau, Justine Attal, Aurore Siegfried, Jean Darcourt, Christophe Cognard, Nicolas Menjot de Champfleur, Fabrice Bonneville

“…<h4>Results</h4> Out of 25 patients, 11 (44%) were classified with pseudoprogression and 14 (56%) with true progression based on the Response Assessement in Neuro-Oncology criteria. rCBVmax was lower for pseudoprogression (3.4 vs. 7.6; p = 0.033) on early follow-up MRI. …”
Get full text

Keep Your Mask On: The Benefits of Masking for Behavior and the Contributions of Aging and Disease on Dysfunctional Masking Pathways by Andrew J. Gall, Dorela D. Shuboni-Mulligan

Get full text

Pediatric Suprasellar Germ Cell Tumors: A Clinical and Radiographic Review of Solitary vs. Bifocal Tumors and Its Therapeutic Implications by Darian R. Esfahani, Tord Alden, Arthur DiPatri, Guifa Xi, Stewart Goldman, Tadanori Tomita

Get full text

Convection-Enhanced Delivery of a First-in-Class Anti-β1 Integrin Antibody for the Treatment of High-Grade Glioma Utilizing Real-Time Imaging by Chibueze D. Nwagwu, Amanda V. Immidisetti, Gabriela Bukanowska, Michael A. Vogelbaum, Anne-Marie Carbonell

Get full text

Prognostic Factors and Histopathological Features of Pediatric Intracranial Ependymomas: Nationwide Brain Tumor Registry-based Study of Japan by Takahiro SASAKI, Yuji UEMATSU, Junya FUKAI, Shota TANAKA, Akitake MUKASA, Nobuhito SAITO, Yoshitaka NARITA, Naoyuki NAKAO

Get full text

Intrathecal trastuzumab versus alternate routes of delivery for HER2-targeted therapies in patients with HER2+ breast cancer leptomeningeal metastases by Anna-Maria Lazaratos, Sarah M. Maritan, Andrea Quaiattini, Amelie Darlix, Ivica Ratosa, Emanuela Ferraro, Gaia Griguolo, Valentina Guarneri, Alessia Pellerino, Silvia Hofer, William Jacot, Hans-Joachim Stemmler, Marcel P.H. van den Broek, Nika Dobnikar, Francois Panet, Zubin Lahijanian, Aki Morikawa, Andrew D. Seidman, Riccardo Soffietti, Lawrence Panasci, Kevin Petrecca, April A.N. Rose, Nathaniel Bouganim, Matthew Dankner

Get full text

Fitness-to-drive for glioblastoma patients by Silvia Hofer, Kristina Keller, Lukas Imbach, Ulrich Roelcke, Gregor Hutter, Thomas Hundsberger, Caroline Hertler, Emilie Le Rhun, Flavio Vasella, Dominik Cordier, Marian Neidert, Andreas Hottinger, Denis Migliorini, Tobias Pflugshaupt, Noemi Eggenberger, Brigitta Baumert, Heinz Läubli, Dorothee Gramatzki, Michael Reinert, Gianfranco Pesce, Philippe Schucht, Irene Frank, Dirk Lehnick, Tobias Weiss, Hans-Georg Wirsching, Fabian Wolpert, Patrick Roth, Michael Weller

“… OBJECTIVE The management of brain tumour patients who would like to resume driving is complex, and needs multidisciplinary input and a consensus among treating physicians. The Swiss Neuro-Oncology Society (SwissNOS) and the Swiss Society for Legal Medicine (SGRM) aim to provide guidance on how to assess “fitness-to-drive” of glioblastoma patients and to harmonise the relevant procedures in Switzerland. …”
Get full text

A pharmacoeconomic analysis from Italian guidelines for the management of prolactinomas by Michele Basile, Ilaria Valentini, Roberto Attanasio, Renato Cozzi, Agnese Persichetti, Irene Samperi, Alessandro Scoppola, Renata Simona Auriemma, Ernesto De Menis, Felice Esposito, Emanuele Ferrante, Giuseppe Iatì, Diego Mazzatenta, Maurizio Poggi, Roberta Rudà, Fabio Tortora, Fabio Cruciani, Zuzana Mitrova, Rosella Saulle, Simona Vecchi, Paolo Cappabianca, Agostino Paoletta, Alessandro Bozzao, Marco Caputo, Francesco Doglietto, Francesco Ferraù, Andrea Gerardo Lania, Stefano Laureti, Stefano Lello, Davide Locatelli, Pietro Maffei, Giuseppe Minniti, Alessandro Peri, Chiara Ruini, Fabio Settanni, Antonio Silvani, Nadia Veronese, Franco Grimaldi, Enrico Papini, Americo Cicchetti

Get full text

Evofosfamide Is Effective against Pediatric Aggressive Glioma Cell Lines in Hypoxic Conditions and Potentiates the Effect of Cytotoxic Chemotherapy and Ionizing Radiations by Quentin Bailleul, Pauline Navarin, Mélanie Arcicasa, Christine Bal-Mahieu, Angel Montero Carcaboso, Xuefen Le Bourhis, Alessandro Furlan, Samuel Meignan, Pierre Leblond

“…In this study, we evaluated its potential in the field of pediatric neuro-oncology. We assessed the efficacy of Evo in vitro as a single drug, or in combination with SN38, doxorubicin, and etoposide, against three pediatric high-grade glioma (pHGG) and three diffuse intrinsic pontine glioma (DIPG) cell lines under hypoxic conditions. …”
Get full text

Pertuzumab plus high-dose trastuzumab for HER2-positive breast cancer with brain metastases: PATRICIA final efficacy data by Nancy U. Lin, Priya Kumthekar, Solmaz Sahebjam, Nuhad Ibrahim, Anita Fung, Anna Cheng, Alan Nicholas, Jesse Sussell, Mark Pegram

“…Primary endpoint: confirmed ORR (CNS) per Response Assessment in Neuro-Oncology Brain Metastases criteria. Secondary endpoints were response duration, CBR, progression-free survival (PFS), overall survival (OS), safety, and PROs. …”
Get full text

Histologic Definition of Enhancing Core and FLAIR Hyperintensity Region of Glioblastoma, IDH-Wild Type: A Clinico-Pathologic Study on a Single-Institution Series by Giuseppe Broggi, Roberto Altieri, Valeria Barresi, Francesco Certo, Giuseppe Maria Vincenzo Barbagallo, Magda Zanelli, Andrea Palicelli, Gaetano Magro, Rosario Caltabiano

“…The extent of resection beyond the enhancing core (EC) in glioblastoma IDH-wild type (GBM, IDHwt) is one of the most debated topics in neuro-oncology. Indeed, it has been demonstrated that local disease recurrence often arises in peritumoral areas and that radiologically-defined FLAIR hyperintensity areas of GBM IDHwt are often visible beyond the conventional EC. …”
Get full text

Evolution of a Meningothelial Meningioma: From WHO Grade 1 to Anaplastic Grade 3 with Extracranial Metastasis Including Extensive Liver Metastasis by Christer Ruff, Paula Bombach, Georg Gohla, Till-Karsten Hauser, Frank Paulsen, Nick Farhang, Hans Boesmueller, Rudi Beschorner, Malte Bongers

Get full text

Targeted Chemometrics Investigations of Source-, Age- and Gender-Dependencies of Oral Cavity Malodorous Volatile Sulphur Compounds by Kerry L. Grootveld, Victor Ruiz-Rodado, Martin Grootveld

Get full text

fMRI Retinotopic Mapping in Patients with Brain Tumors and Space-Occupying Brain Lesions in the Area of the Occipital Lobe by Katharina Hense, Tina Plank, Christina Wendl, Frank Dodoo-Schittko, Elisabeth Bumes, Mark W. Greenlee, Nils Ole Schmidt, Martin Proescholdt, Katharina Rosengarth

Get full text

Does a Single Exposure to General Anesthesia Have a Cumulative Effect on the Developing Brain after Mild Perinatal Asphyxia? by Sebastian Isac, Bogdan Pavel, Maria Dobre, Elena Milanesi, Irina-Mihaela Matache, Raul-Mihai Paun, Artsiom Klimko, Mara Ioana Iesanu, Gabriela Droc, Ana-Maria Zagrean

Get full text

Visualization, navigation, augmentation. The ever-changing perspective of the neurosurgeon by A. Boaro, F. Moscolo, A. Feletti, G.M.V. Polizzi, S. Nunes, F. Siddi, M.L.D. Broekman, F. Sala

“…The most frequent application setting for AR is brain surgery (71.6%), specifically neuro-oncology (36.2%) and microscope-based (29.2%), even though in the majority of cases AR applications presented their own visualization supports (66%). …”
Get full text

Macrophage and Lymphocyte Infiltration Is Associated with Volumetric Tumor Size but Not with Volumetric Growth in the Tübingen Schwannoma Cohort by Vítor Moura Gonçalves, Elisa-Maria Suhm, Vanessa Ries, Marco Skardelly, Ghazaleh Tabatabai, Marcos Tatagiba, Jens Schittenhelm, Felix Behling

Get full text

Advances in Preclinical/Clinical Glioblastoma Treatment: Can Nanoparticles Be of Help? by Daniel Ruiz-Molina, Xiaoman Mao, Paula Alfonso-Triguero, Julia Lorenzo, Jordi Bruna, Victor J. Yuste, Ana Paula Candiota, Fernando Novio

Get full text